Skip to Content
MilliporeSigma
  • Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.

Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.

The American journal of gastroenterology (2013-01-16)
M J Casanova, M Chaparro, E Domènech, M Barreiro-de Acosta, F Bermejo, E Iglesias, F Gomollón, L Rodrigo, X Calvet, M Esteve, E García-Planella, S García-López, C Taxonera, M Calvo, M López, D Ginard, M Gómez-García, E Garrido, J L Pérez-Calle, B Beltrán, M Piqueras, C Saro, B Botella, C Dueñas, A Ponferrada, M Mañosa, V García-Sánchez, J Maté, J P Gisbert
ABSTRACT

The safety of thiopurines and anti-tumor necrosis factor-α (TNF-α) drugs during pregnancy remains controversial, as the experience with these drugs in this situation is limited. Our aim is to assess the safety of thiopurines and anti-TNF-α drugs for the treatment of inflammatory bowel disease (IBD) during pregnancy. Retrospective, multicenter study in IBD patients. Pregnancies were classified according to the therapeutic regimens during pregnancy or during the 3 months before the conception: non-exposed group, pregnancies exposed to thiopurines alone (group A), and pregnancies exposed to anti-TNF-α drugs (group B). An unfavorable Global Pregnancy Outcome (GPO) was considered if pregnancy developed with obstetric complications in the mother and in the newborn. A total of 187 pregnancies in the group A, 66 pregnancies in the group B, and 318 pregnancies in the non-exposed group were included. The rate of unfavorable GPO was different among the three groups (31.8% in non-exposed group, 21.9% in group A, and 34.8% in group B), being lower in pregnancies under thiopurines than among non-exposed (P = 0.01). The rate of pregnancy complications was similar among the three groups (27.7% in non-exposed, 20.9% in group A, and 30.3% in group B). The rate of neonatal complications was different among the three groups (23.3% in non-exposed group, 13.9% in group A, and 21.2% in group B), being lower in pregnancies under thiopurines than among non-exposed (P = 0.01). In the multivariate analysis, the treatment with thiopurines (odds ratio = 0.6; 95% confidence interval = 0.4-0.9, P = 0.02) was the only predictor of favorable GPO, whereas maternal age >35 years at conception was the only predictor of unfavorable GPO. The treatment with anti-TNF-α drugs was not associated with an unfavorable GPO. The treatment with thiopurines and anti-TNF-α drugs does not seem to increase the risk of complications during pregnancy and does seem to be safe for the newborn.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
6-Mercaptopurine monohydrate, 98%